3-脱氧-d-葡萄糖 | 2490-91-7

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-脱氧-d-葡萄糖
• 中文别名: 3-脱氧-D-葡萄糖
• 英文名称: 3-deoxy-D-glucose
• 英文别名: 3-deoxyglucosone；2-deoxyglucose；D-ribo-3-deoxy-hexose；aldehydo-D-ribo-3-Desoxy-hexose；D-ribo-2,4,5,6-Tetrahydroxy-hexanal；D-ribo-3-Desoxy-hexose；(2R,4S,5R)-2,4,5,6-tetrahydroxyhexanal
• CAS: 2490-91-7
• 化学式: C₆H₁₂O₅
• 分子量: 164.158
• InChiKey: KDSPLKNONIUZSZ-NGJCXOISSA-N

物化性质

• 熔点：
  129-131°C
• 沸点：
  481℃
• 密度：
  1.414
• 闪点：
  259℃
• 溶解度：
  水（稍微加热）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 海关编码：
  2912491000

反应信息

• 作为反应物：
  描述：

  3-脱氧-d-葡萄糖 在 盐酸 、 氧气 、 sodium hydroxide 、 catalase 作用下， 以 水 为溶剂， 反应 10.0h， 生成 5-羟甲基糠醛
  参考文献：
  名称：

  Reactivity of Thermally Treated α-Dicarbonyl Compounds

  摘要：

  The degradation reaction of thermally treated 3-deoxy-D-erythro-hexos-2-ulose and methylglyoxal, both key intermediates in Mail lard chemistry, was investigated. Different analytical strategies were accomplished to cover the broad range of formed products and their different chemical behavior. These involved HPLC-DAD and accordingly LC/MS analysis of the quinoxaline derivates, GC/MS analysis of the acetylated quinoxalines, and GC-FID analysis of the decyl ester of acetic acid. As a main degradation product of 3-deoxy-D-erythro-hexos-2-ulose, 5-(hydroxymethyl)furfural could be identified. At alkaline pH values, 3-deoxy-D-erythro-hexos-2-ulose generated various acids but no colored products. In contrast, thermal treatment of methylglyoxal yielded high molecular weight, brownish products. A dimer of methylglyoxal, first precursor for aldol-based polymerization of methylglyoxal, could be clearly identified by GC/MS.

  DOI：

  10.1021/jf302959k
• 作为产物：
  描述：

  双丙酮葡萄糖 在 咪唑 、 硫酸 、 三正丁基氢锡 、 sodium hydride 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 5.0h， 生成 3-脱氧-d-葡萄糖
  参考文献：
  名称：

  Reactivity of Thermally Treated α-Dicarbonyl Compounds

  摘要：

  The degradation reaction of thermally treated 3-deoxy-D-erythro-hexos-2-ulose and methylglyoxal, both key intermediates in Mail lard chemistry, was investigated. Different analytical strategies were accomplished to cover the broad range of formed products and their different chemical behavior. These involved HPLC-DAD and accordingly LC/MS analysis of the quinoxaline derivates, GC/MS analysis of the acetylated quinoxalines, and GC-FID analysis of the decyl ester of acetic acid. As a main degradation product of 3-deoxy-D-erythro-hexos-2-ulose, 5-(hydroxymethyl)furfural could be identified. At alkaline pH values, 3-deoxy-D-erythro-hexos-2-ulose generated various acids but no colored products. In contrast, thermal treatment of methylglyoxal yielded high molecular weight, brownish products. A dimer of methylglyoxal, first precursor for aldol-based polymerization of methylglyoxal, could be clearly identified by GC/MS.

  DOI：

  10.1021/jf302959k

文献信息

• [EN] RAPAMYCIN CARBOHYDRATE DERIVATIVES<br/>[FR] DERIVES DE RAPAMYCINE CARBOHYDRATE
  申请人：ISOTECHNIKA INTERNAT INC

  公开号：WO2004101583A1

  公开（公告）日：2004-11-25

  This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.

  这项发明提供了经过改良的雷帕霉素，其具有通过连接剂连接的特定单糖，寡糖，伪糖或其衍生物，从而创造出具有增强药代动力学和/或药效动力学特性的雷帕霉素糖衍生物。例如，给予雷帕霉素糖衍生物的治疗导致了改变的药代动力学特性和降低的毒性。因此，本发明提供了具有与其他同类药物（如雷帕霉素）不同特性的化合物。
• Modulators of Hypoxia Inducible Factor-1 and Related Uses
  申请人：Gardiner Gregory

  公开号：US20090023666A1

  公开（公告）日：2009-01-22

  The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.

  这项发明涉及公式I或II的化合物：以及这些化合物的药用盐和前药，以及使用这些化合物调节局部和全身缺氧事件效应的方法。
• Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
  申请人：——

  公开号：US20040235712A1

  公开（公告）日：2004-11-25

  In part, the present invention is directed to coordination complexes comprising a therapeutic agent. In one aspect, the subject compositions comprise a platinum metal center and a covalently attached therapeutic agent.

  在某种程度上，本发明涉及包含治疗剂的配位络合物。在一个方面，所述组合物包括铂金属中心和共价连接的治疗剂。
• [EN] CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD<br/>[FR] CONJUGUÉS D'UNE GLYCOPROTÉINE OU D'UN GLYCANE AVEC UNE CHARGE TOXIQUE
  申请人：GLYKOS FINLAND OY

  公开号：WO2014177771A1

  公开（公告）日：2014-11-06

  The invention relates to a glycoprotein-toxic pay- load molecule conjugate, a toxic payload molecule- glycan conjugate, and a pharmaceutical composi- tion.The invention further relates to a method for preparing the glycoprotein-toxic payload mole- cule conjugate, the method for modulating growth of a cell population and a method of treating tu- mour cells.

  这项发明涉及一种糖蛋白-毒性载荷分子结合物、一种毒性载荷分子-糖基结合物和一种药物组合物。该发明还涉及一种制备糖蛋白-毒性载荷分子结合物的方法，一种调节细胞群体生长的方法以及一种治疗肿瘤细胞的方法。
• [EN] POLYBIOTIN COMPOUNDS FOR MAGNETIC RESONANCE IMAGINING AND DRUG DELIVERY<br/>[FR] COMPOSES DE POLYBIOTINE POUR IRM ET ADMINISTRATION DE MEDICAMENTS
  申请人：GEN HOSPITAL CORP

  公开号：WO2005032598A1

  公开（公告）日：2005-04-14

  The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.

  该发明涉及一般用作成像剂和药物传递剂的含生物素化合物。该发明的另一个方面涉及上述化合物螯合到金属原子上。在一个优选实施例中，金属原子是钆。该发明的另一个方面涉及一种包含三个生物素基团和一个与杂环核共价结合的药物剂的化合物。在某些实施例中，药物剂是抗生素、抗病毒药物或放射性核素。本发明的另一个方面涉及一种涉及向哺乳动物施用该发明化合物以治疗疾病的方法。本发明的另一个方面涉及使用该发明化合物获得磁共振图像的方法。